- Datum28.10.2025
- Uhrzeit18:00 - 19:00 Uhr
- Veranstalter
stock3
Ingmar Königshofen
Moderator
Novartis AG Nam.-Akt. (Sp.ADRs)/1 SF 20 Aktie
Verkaufen
Kaufen
Novartis AG Nam.-Akt. (Sp.ADRs)/1 SF 20 Chart
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren
Novartis AG Nam.-Akt. (Sp.ADRs)/1 SF 20 Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (NYSE)
0,50 %
Intraday
1,79 %
1 Woche
6,91 %
1 Monat
35,06 %
Seit Jahresbeginn
12,16 %
1 Jahr
73,96 %
3 Jahre
53,36 %
5 Jahre
42,35 %
10 Jahre
Passender Service zu Novartis AG Nam.-Akt. (Sp.ADRs)/1 SF 20
Webinar zu Novartis AG Nam.-Akt. (Sp.ADRs)/1 SF 20
Kursinformationen (NYSE)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)96,062-133,550
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Novartis AG Nam.-Akt. (Sp.ADRs)/1 SF 20
| Ex-Datum | Fiskaljahr | Dividende | Rendite |
|---|---|---|---|
| - | 2027 (e) | ||
| - | 2026 (e) | ||
| - | 2025 (e) | ||
| 12.03.2025 | 2024 | 3,993991 $ | 3,59 % |
| 07.03.2024 | 2023 | 3,7395445 $ | 3,64 % |
| 09.03.2023 | 2022 | 3,4986993 $ | 4,20 % |
| 08.03.2022 | 2021 | 3,3252497 $ | 3,98 % |
| 04.03.2021 | 2020 | 3,1990725 $ | 3,65 % |
| 03.03.2020 | 2019 | 3,0873655 $ | 3,55 % |
| 04.03.2019 | 2018 | 2,834128 $ | 3,10 % |
| 06.03.2018 | 2017 | 2,936451 $ | 3,48 % |
| 01.03.2017 | 2016 | 2,717759 $ | 3,48 % |
| 24.02.2016 | 2015 | 2,717946 $ | 3,69 % |
| 02.03.2015 | 2014 | 2,665947 $ | 2,60 % |
| 27.02.2014 | 2013 | 2,759789 $ | 3,31 % |
| 26.02.2013 | 2012 | 2,42647 $ | 3,51 % |
| 27.02.2012 | 2011 | 2,482145 $ | - |
| 24.02.2011 | 2010 | 2,36336 $ | - |
| 02.03.2010 | 2009 | 1,948359 $ | - |
| 24.02.2009 | 2008 | 1,714383 $ | - |
| 26.02.2008 | 2007 | 1,537471 $ | - |
| 06.03.2007 | 2007 | 1,096517 $ | - |
| 28.02.2006 | 2005 | 1,15 Fr | - |
| 01.03.2005 | 2004 | 1,05 Fr | - |
| 24.02.2004 | 2003 | 0,02375 Fr | - |
| 04.03.2003 | 2002 | 0,95 Fr | - |
| 21.03.2002 | 2001 | 0,90 Fr | - |
| 22.03.2001 | 2000 | 0,80 Fr | - |
| 12.04.2000 | 1999 | 0,80 Fr | - |
| 21.04.1999 | 1998 | 0,725 Fr | - |
| 21.04.1998 | 1997 | 0,625 Fr | - |
Termine von Novartis AG Nam.-Akt. (Sp.ADRs)/1 SF 20
Keine aktuellen Termine
Beschreibung
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.